Ajai Chari, MD
Enriched profileClinical Professor of Medicine; Director, Multiple Myeloma Program · University of California, San Francisco (UCSF)
Ajai Chari is Clinical Professor of Medicine; Director, Multiple Myeloma Program at University of California, San Francisco (UCSF). OpenAlex indexes 487 publications with 14,361 citations (h-index 51); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Ajai Chari, MD, is Clinical Professor of Medicine at University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, Division of Hematology/Oncology. The public record shows 487 publications with 14,361 citations (h-index 51), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 29 companies.
- Most recent indexed publication: 2025 · Nature genetics
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 181.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Delayed Toxicities Post-CAR-T
Sponsor: Icahn School of Medicine at Mount Sinai
- Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor: Ajai Chari
- Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Sponsor: Icahn School of Medicine at Mount Sinai
Industry payments
Updated 14 Oct 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20254 payments$22,079openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year202524 payments$15,854openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78.9%Thalidomide Analog78.9%Revlimid71%Lenalidomide29%Part D<11 patientsDermatology
21.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.1%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
102 congress contributions (2012–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Impact of low disease burden on the safety and efficacy of BCMA CAR-T in patients with Relapsed/Refractory multiple myeloma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
Blood cancer discovery
Article2024
Most-cited works
by citation count (OpenAlex)- 01Teclistamab in Relapsed or Refractory Multiple Myeloma1,130 citations2022
- 02
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ajai-chari-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Ajai-Chari-15570763
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/AjaiChari
Mentions by others
where others cite or feature them- X / Twitter
X (Twitter): @AjaiChari
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Internal Medicine Residency
New York Presbyterian Hospital/Columbia University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
- Board Certified
Hematology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Editorial & leadership roles
journal and society appointments- Director
Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Principal Investigator
investigator-initiated and national/international industry-sponsored multiple myeloma clinical trials
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Secondary affiliations
appointments beyond the home institution- 600 16th Street
#N472C, San Francisco, CA 94158 (UCSF Profiles office listing, Mission Bay campus)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Gregory Marcus, MD
University of California, San Francisco (UCSF)
Eric Small, MD
University of California, San Francisco (UCSF)
Adam Boxer, MD
University of California, San Francisco (UCSF)
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens